Excellent
Fully Aligned
Patient Risk:
Low
Summary
The evaluated claim is directly supported by the provided FDA label text (Warnings/Precautions 5.1 and Patient Counseling 17) and aligns with the described need for close clinical and laboratory monitoring after discontinuation.
Category Scores
Accurate Statements
Post-treatment acute exacerbation (flare) of hepatitis B can occur after discontinuation of BIKTARVY.
Supported by label section 5.1 (Severe Acute Exacerbation of Hepatitis B in Patients with HIV-1 and HBV) and reiterated in 17 (Patient Counseling Information).
Patients should be monitored afterward.
Supported by label section 5.1, which instructs close clinical and laboratory follow-up for at least several months after stopping BIKTARVY.
Unsupported Statements
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The claim correctly reflects a label warning and includes the key management element of close monitoring after discontinuation; it does not omit any material qualifier required to support the specific evaluated statement.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Fully Aligned
Primary Issue
Suggested Improvement